Literature DB >> 24167530

One-year evaluation of a neonatal screening program for cystic fibrosis in Switzerland. Problems.

Heinz-Harald Abholz.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24167530      PMCID： PMC3804781          DOI： 10.3238/arztebl.2013.0676a

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  One-year evaluation of a neonatal screening program for cystic fibrosis in Switzerland.

Authors:  Corina S Rueegg; Claudia E Kuehni; Sabina Gallati; Matthias Baumgartner; Toni Torresani; Juerg Barben
Journal:  Dtsch Arztebl Int       Date:  2013-05-17       Impact factor: 5.594

2.  Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre.

Authors:  F Nicole Dijk; Karen McKay; Federica Barzi; Kevin J Gaskin; Dominic A Fitzgerald
Journal:  Arch Dis Child       Date:  2011-10-12       Impact factor: 3.791

Review 3.  Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.

Authors:  Scott D Grosse; Coleen A Boyle; Jeffrey R Botkin; Anne Marie Comeau; Martin Kharrazi; Margaret Rosenfeld; Benjamin S Wilfond
Journal:  MMWR Recomm Rep       Date:  2004-10-15

4.  European best practice guidelines for cystic fibrosis neonatal screening.

Authors:  Carlo Castellani; Kevin W Southern; Keith Brownlee; Jeannette Dankert Roelse; Alistair Duff; Michael Farrell; Anil Mehta; Anne Munck; Rodney Pollitt; Isabelle Sermet-Gaudelus; Bridget Wilcken; Manfred Ballmann; Carlo Corbetta; Isabelle de Monestrol; Philip Farrell; Maria Feilcke; Claude Férec; Silvia Gartner; Kevin Gaskin; Jutta Hammermann; Nataliya Kashirskaya; Gerard Loeber; Milan Macek; Gita Mehta; Andreas Reiman; Paolo Rizzotti; Alec Sammon; Dorota Sands; Alan Smyth; Olaf Sommerburg; Toni Torresani; Georges Travert; Annette Vernooij; Stuart Elborn
Journal:  J Cyst Fibros       Date:  2009-02-26       Impact factor: 5.482
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.